Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: July 8, 2013
Last updated: October 3, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)